Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record.

Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients

Open access
Noe[Combining Diaeresis]l, Christian, Abramowicz, Daniel, Durand, Dominique, Mourad, Georges, Lang, Philippe, Kessler, Miche[Combining Grave Accent]le, Charpentier, Bernard, Touchard, Guy, Berthoux, Franc[COMBINING CEDILLA]ois, Merville, Pierre, Ouali, Nacera, Squifflet, Jean-Paul, Bayle, Franc[COMBINING CEDILLA]ois, Wissing, Karl Martin, Hazzan, Marc·2009·Journal of the American Society of Nephrology

Abstract

Nondepleting anti-CD25 monoclonal antibodies (daclizumab) and depleting polyclonal antithymocyte globulin (Thymoglobulin) both prevent acute rejection, but these therapies have not been directly compared in a high-risk, HLA-sensitized renal transplant population. We randomly assigned 227 patients, who were about to receive a kidney graft from a deceased donor, to either Thymoglobulin or daclizumab if they met one of the following risk factors: current panel reactive antibodies (PRA) >30%; peak PRA >50%; loss of a first kidney graft from rejection within 2 yr of transplantation; or two or three previous grafts. Maintenance immunosuppression comprised tacrolimus, mycophenolate mofetil, and steroids. Compared with the daclizumab group, patients treated with Thymoglobulin had a lower incidence of both biopsy-proven acute rejection (15.0% versus 27.2%; P = 0.016) and steroid-resistant rejection (2.7% versus 14.9%; P = 0.002) at one year. One-year graft and patient survival rates were similar between the two groups. In a comparison of rejectors and nonrejectors, overall graft survival was significantly higher in the rejection-free group (87.2% versus 75.0%; P = 0.037). In conclusion, among high-immunological-risk renal transplant recipients, Thymoglobulin is superior to daclizumab for the prevention of biopsy-proven acute rejection, but there is no significant benefit to one-year graft or patient survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2008101037

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 199

Metadata

Authors
Noe[Combining Diaeresis]l, C., Abramowicz, D., Durand, D., Mourad, G., Lang, P., Kessler, M. G. A., Charpentier, B., Touchard, G., Berthoux, F. C., Merville, P., Ouali, N., Squifflet, J.-P., Bayle, F. C., Wissing, K. M., & Hazzan, M.
Venue
Journal of the American Society of Nephrology
Published
2009-06
Volume
20
Issue
6
Pages
1385-1392
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2135136335
Cited by
199
References
0
FWCI
7.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients. https://app.cochat.ai/papers/10.1681/asn.2008101037
The paper
Noe[Combining Diaeresis]l, C., Abramowicz, D., Durand, D., Mourad, G., Lang, P., Kessler, M. G. A., Charpentier, B., Touchard, G., Berthoux, F. C., Merville, P., Ouali, N., Squifflet, J.-P., Bayle, F. C., Wissing, K. M., & Hazzan, M. (2009). Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2008101037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.